All In Biotech

Drug Trial Radar · NCT07828353

A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

A Multicenter, Randomized, Blinded, Placebo-Controlled Confirmatory Clinical Trial of Autologous REGEND001 Cell Therapy for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Regend TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • PlaceboBiological

    Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of placebo via bronchoscopy and 1 year of follow-up.

  • REGEND001Biological

    Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of REGEND001 via bronchoscopy and 1 year of follow-up.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the measured Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)Time frame: Week 52 after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.